Diffuse large B-cell lymphoma (DLBCL or DLBL)

​

Diffuse large B-cell lymphoma (DLBCL or DLBL) is a cancer of B cells, a type of white blood cell responsible for producing antibodies. It is the most common type of non-Hodgkin lymphoma among adults, with an annual incidence of 7–8 cases per 100,000 people per year in the USA and the UK. This cancer occurs primarily in older individuals, with a median age of diagnosis at approximately 70 years of age, though it can also occur in children and young adults in rare cases. DLBCL is an aggressive tumor which can arise in virtually any part of the body,and the first sign of this illness is typically the observation of a rapidly growing mass, sometimes associated with B symptoms—fever, weight loss, and night sweats.

Usually DLBCL arises from normal B cells, but it can also represent a malignant transformation of other types of lymphoma or leukemia. An underlying immunodeficiency is a significant risk factor. Infection with Epstein–Barr virus has also been found to contribute to the development of some subgroups of DLBCL.

DLBCL typically replaces the normal lymph node architecture in a diffuse pattern. Cytologically, are diverse and can be divided into the following morphologic variants: Centroblastic, Immunoblastic, T-cell/histiocyte rich and Anaplastic.

​

Case-1

​

​

​

​

​

​

​

​

​

 

 

 

 

 

 

 

 

 

 

Above case shows (lymph- red, gran-blue, mono-pink) positivity for CD19,CD20, CD10, CD22,  sIgM and negativity for CD5, CD23

 

References

• Morgan G, Vornanen M, Puitinen J et al (1997) Changing trends in the incidence of non-Hodgkin’s lymphoma in Europe. Ann Oncol 8(2):49–54PubMed

• Shiels MS, Engels EA, Linet MS et al (2013) The epidemic of non-Hodgkin lymphoma in the United States: disentangling the effect of HIV, 1992-2009. Cancer Epidemiol Biomarkers Prev 22:1069–1078PubMed

• Coiffier B (2001) Diffuse large cell lymphoma. Curr Opin Oncol 13:325–334PubMed

• Lossos IS (2005) Molecular pathogenesis of diffuse large B-cell lymphoma. J Clin Oncol 23:6351–6357PubMed

• Green TM, Young KH, Visco C et al (2012) Immunohistochemical double-hit score is a strong predictor of outcome in patients with diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. J Clin Oncol 30:3460–3467PubMed

• Johnson NA, Slack GW, Savage KJ et al (2012) Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. J Clin Oncol 30:3452–3459PubMed

• Horn H, Ziepert M, Becher C et al (2013) MYC status in concert with BCL2 and BCL6 expression predicts outcome in diffuse large B-cell lymphoma. Blood 121:2253–2263PubMed

• Dunleavy K, Wayne AS, Shovlin M et al (2011) MYC+aggressive B-cell lymphomas: novel therapy for untreated Burktit lymphoma and MYC+diffuse large B-cell lymphoma with DA-EPOCH-R. Ann Oncol 22:iv106Google Scholar

• Barrans S, Crouch S, Smith A et al (2010) Rearrangement of MYC is associated with poor prognosis in patients with diffuse large B-cell lymphoma treated in the era of rituximab. J Clin Oncol 28:3360–3365PubMed

• Cuccuini W, Briere J, Mounier N et al (2012) MYC+diffuse large B-cell lymphoma is not salvaged by classical R-ICE or R-DHAP followed by BEAM plus autologous stem cell transplantation. Blood 119:4619–4624PubMed

• Dave SS, Fu K, Wright GW et al (2006) Molecular diagnosis of Burkitt’s lymphoma. N Engl J Med 354:2431–2442PubMed